Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis

摘要

Nivolumab and pembrolizumab can cause immune-related adverse events (irAE). In this retrospective chart review of advanced non-small-cell lung cancer patients receiving programmed death 1 antibodies in British Columbia, Canada, treatment interruption due to irAE was associated with a lower median overall survival (OS) than those treated continuously. Development of colitis in nivolumab-treated patients was associated with shorter OS than for patients who did not develop colitis.